Perspective Gets FDA Fast Track For PSV359 In Rare SFTs
Perspective Therapeutics announced FDA Fast Track Designation for PSV359 treating rare fibroblast activation protein-positive solitary fibrous tumors.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed